Daan J. A. Crommelin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daan J. A. Crommelin has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Wim Jiskoot
Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
6 shared publications Gert Storm
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, The Netherlands
5 shared publications- Enrico Mastrobattista
Utrecht University
4 shared publications - Wim E. Hennink
Division of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
4 shared publications Wim Jiskoot
Leiden University
4 shared publicationsAndrea Hawe
Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany
3 shared publications
Latest Publications
- 25 July 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (12) , 103926
In memory of Professor William I. Higuchi (1931–2024)
- 25 July 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (12) , 103926
In memory of Professor William I. Higuchi (1931–2024)
- 30 January 2024
- Published by Springer Nature
- p. 531-544
Interferons and Interleukins
- 30 January 2024
- Published by Springer Nature
- p. 95-117
Formulation of Biologics Including Biopharmaceutical Considerations
- 30 January 2024
- Published by Springer Nature
- p. 95-117
Formulation of Biologics Including Biopharmaceutical Considerations
- 30 January 2024
- Published by Springer Nature
- p. 29-41
Biophysical and Biochemical Characteristics of Therapeutic Proteins
- 30 January 2024
- Published by Springer Nature
- p. 29-41
Biophysical and Biochemical Characteristics of Therapeutic Proteins
- 30 January 2024
- Published by Springer Nature
- p. 503-514
Human Growth Hormone
- 16 June 2023
- Published by Springer Nature
- p. 551-590
Therapeutic Proteins and Advanced Therapy Medicinal Products
- 16 June 2023
- Published by Springer Nature
- p. 551-590
Therapeutic Proteins and Advanced Therapy Medicinal Products
- Top Cited PapersOpen Access
- 6 November 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 112 (2) , 386-403
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
- 6 November 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 112 (2) , 386-403
Top Cited PapersOpen AccessThe Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
- Top Cited Papers
- 7 April 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (4) , 337-346
Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines
After over a billion of vaccinations with messenger RNA-lipid nanoparticle (mRNA-LNP) based SARS-CoV-2 vaccines, anaphylaxis and other manifestations of hypersensitivity can be considered as very rare adverse events. Although current recommendations include avoiding a second dose in those with first-dose anaphylaxis, the underlying mechanisms are unknown; therefore, the risk of a future reaction cannot be predicted. Given how important new mRNA constructs will be to address the emergence of new viral variants and viruses, there is an urgent need for clinical approaches that would allow a safe repeated immunization of high-risk individuals and for reliable predictive tools of adverse reactions to mRNA vaccines. In many aspects, anaphylaxis symptoms experienced by the affected vaccine recipients resemble those of infusion reactions to nanomedicines. Here we share lessons learned over a decade of nanomedicine research and discuss the current knowledge about several factors that individually or collectively contribute to infusion reactions to nanomedicines. We aim to use this knowledge to inform the SARS-CoV-2 lipid-nanoparticle-based mRNA vaccine field.
- 7 April 2022
- Published by Springer Nature in Nature Nanotechnology
- Vol. 17 (4) , 337-346
Top Cited PapersApplying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines
After over a billion of vaccinations with messenger RNA-lipid nanoparticle (mRNA-LNP) based SARS-CoV-2 vaccines, anaphylaxis and other manifestations of hypersensitivity can be considered as very rare adverse events. Although current recommendations include avoiding a second dose in those with first-dose anaphylaxis, the underlying mechanisms are unknown; therefore, the risk of a future reaction cannot be predicted. Given how important new mRNA constructs will be to address the emergence of new viral variants and viruses, there is an urgent need for clinical approaches that would allow a safe repeated immunization of high-risk individuals and for reliable predictive tools of adverse reactions to mRNA vaccines. In many aspects, anaphylaxis symptoms experienced by the affected vaccine recipients resemble those of infusion reactions to nanomedicines. Here we share lessons learned over a decade of nanomedicine research and discuss the current knowledge about several factors that individually or collectively contribute to infusion reactions to nanomedicines. We aim to use this knowledge to inform the SARS-CoV-2 lipid-nanoparticle-based mRNA vaccine field.
- Top Cited PapersOpen Access
- 1 April 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (4) , 861-867
Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?
- 1 April 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (4) , 861-867
Top Cited PapersOpen AccessOngoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?
- 15 December 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
A Cluster of Articles in Memory of Wim Jiskoot, Ph.D.
- 15 December 2021
- Published by Elsevier in Journal of Pharmaceutical Sciences
A Cluster of Articles in Memory of Wim Jiskoot, Ph.D.